Pradaxa Medicare Study: Observing a Slow Attitude Change at FDA on Observational Studies
This article was originally published in RPM Report
CDER Deputy Director Bob Temple is a confirmed skeptic of the value of observational trial data to FDA’s regulatory decisions. A recent Medicare study on the bleeding risks associated with Boehringer-Ingelheim’s Pradaxa, however, confirmed an earlier position on the drug by FDA and meets with Temple’s approbation.
You may also be interested in...
Will Real-World Data Sway Course Of Novel Anticoagulant Market?
A wave of data to support use of novel anticoagulants in real-world settings was presented at the European Society of Cardiology Congress, but the question is whether this will alter the course of the market still dominated by warfarin and trailed by J&J/Bayer's Xarelto.
Reality Check For Real World Data: FDA’s Sentinel Network Enters “Production” Stage
FDA’s Sentinel drug safety surveillance network has completed an important transition, moving from “experimental” to “production stage” as a tool to help inform post-market safety decisions. Now the question is whether real-world data can be used in making efficacy decisions.
BI’s Pradaxa Gets Mixed Reviews In Postmarketing Studies
Two observational studies of Medicare patients reach different conclusions on Pradaxa bleeding rates, but FDA says risk/benefit profile of drug has not changed.